Patents by Inventor Gerd Sutter

Gerd Sutter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vaccinia virus MVA-E3L-knockout-mutants and use thereof
    Patent number: 7049145
    Abstract: The present invention relates to mutant MVA vaccinia viruses, which are used for the generation of recombinant MVA viruses, as well as host cells, which have been infected with these mutant MVA viruses. The present invention further relates to DNA-vector constructs, and a method for the generation of recombinant MVA by using the mutant MVA viruses and the DNA-vector constructs. The mutant MVA vaccinia viruses of the present invention are characterized in that the MVA ORF 050L gene or a functional part thereof has been inactivated in the viral genome.
    Type: Grant
    Filed: September 11, 2002
    Date of Patent: May 23, 2006
    Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit, GmbH
    Inventors: Volker Erfle, Simone Hornemann, Gerd Sutter
  • Method of generating recombinant MVA
    Publication number: 20060002896
    Abstract: The present invention relates to MVA mutants, which can be used for the generation of recombinant MVA viruses, as well as host cells, which have been infected with these mutant MVA viruses. The present invention further relates to DNA-vector constructs, and a method for the generation of recombinant MVA by using the mutant MVA viruses and the DNA-vector constructs.
    Type: Application
    Filed: June 10, 2005
    Publication date: January 5, 2006
    Inventors: Caroline Staib, Marianne Loewel, Volker Erfle, Gerd Sutter
  • Recombinant fowlpox virus
    Publication number: 20050287162
    Abstract: The invention relates to a recombinant fowlpox virus (FWPV) and a DNA vector containing gene sequences for one such recombinant fowlpox virus. The invention also relates to a pharmaceutical composition containing said recombinant fowlpox virus or a DNA vector, to the use of said recombinant fowlpox virus for treating infectious diseases or tumour diseases, and to a method for producing said recombinant fowlpox virus or DNA vector. The invention further relates to eukaryote cells or prokaryote cells containing the recombinant DNA vector or the recombinant fowlpox virus. The invention is based on the identification of the FWPV-F11L gene as a novel insertion site for foreign DNA.
    Type: Application
    Filed: May 13, 2003
    Publication date: December 29, 2005
    Inventors: Robert Baier, Denise Boulanger, Volker Erfle, Gerd Sutter
  • Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
    Patent number: 6869793
    Abstract: Recombinant MVA viruses containing and/or capable of expressing dengue virus antigens and the use of such recombinant MVA for vaccination.
    Type: Grant
    Filed: September 23, 1997
    Date of Patent: March 22, 2005
    Assignee: Bavarian Nordic Research Institute
    Inventors: Mary Jane Cardosa, Gerd Sutter, Volker Erfle
  • Vaccinia virus mva-e3L-knockout-mutants and use thereof
    Publication number: 20050028226
    Abstract: The present invention relates to mutant MVA vaccinia viruses, which are used for the generation of recombinant MVA viruses, as well as host cells, which have been infected with these mutant MVA viruses. The present invention further relates to DNA-vector constructs, and a method for the generation of recombinant MVA by using the mutant MVA viruses and the DNA-vector constructs. The mutant MVA vaccinia viruses of the present invention are characterized in that the MVA ORF 050L gene or a functional part thereof has been inactivated in the viral genome.
    Type: Application
    Filed: September 11, 2002
    Publication date: February 3, 2005
    Inventors: Volker Erfle, Simone Hornemann, Gerd Sutter
  • Recombinant mva capable of expressing structural hcv antigens
    Publication number: 20050019347
    Abstract: The invention relates to recombinant MVA which is capable of expressing structural HCV antigens, functional parts of said structural antigens or epitopes of said structural antigens. The invention further relates to a pharmaceutical composition, especially in the form of a vaccine and containing the recombinant MVA according to the invention, to eukaryotic cells that contain the inventive recombinant MVA and to various uses of the recombinant MVA, for example for producing recombinant structural proteins, for producing a pharmaceutical preparation that is suitable for the therapy and prophylaxis of HCV infections and diseases thereby caused. The invention further relates to methods for producing recombinant MVA and recombinant structural HCV polypeptides encoded by said recombinant MVA, and to DNA or RNA of said recombinant MVA.
    Type: Application
    Filed: September 5, 2002
    Publication date: January 27, 2005
    Inventors: Gerd Sutter, Volker Erfle, Yuan Wang, Guangdi Li, Li-Xin Zhu, Caroline Staib
  • Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
    Publication number: 20040265324
    Abstract: Recombinant MVA viruses containing and/or capable of expressing dengue virus antigens and the use of such recombinant MVA for vaccination.
    Type: Application
    Filed: February 24, 2004
    Publication date: December 30, 2004
    Inventors: Mary Jane Cardosa, Gerd Sutter, Volker Erfle
  • Vector for integration of heterologous sequences into poxviral genomes
    Publication number: 20040228840
    Abstract: A new DNA vector is disclosed comprising a nucleic acid sequence useful for inserting heterologous sequences into the genome of poxviruses by homologous recombination. Also disclosed are recombinant poxviruses carrying heterologous coding sequences transferred by the DNA vector.
    Type: Application
    Filed: September 23, 2003
    Publication date: November 18, 2004
    Applicant: GSF FORSCHUNGSZENTRUM FUR UMWELT UND GESUNDHEIT GMBH
    Inventors: Stefan Wintersperger, Robert Baier, Gerd Sutter, Marion Ohlmann, Volker Erfle
  • Vector for integration of heterologous sequences into poxviral genomes
    Patent number: 6682742
    Abstract: The present invention provides a DNA vector comprising a nucleic acid sequence useful for inserting heterologous sequences into the genome of poxviruses by homologous recombination. The present invention relates also, inter alia, to recombinant poxvirses carrying heterologous coding sequences transferred by the vector according to the present invention.
    Type: Grant
    Filed: December 26, 2001
    Date of Patent: January 27, 2004
    Assignee: GSF Forschungszentrum fur Unwelt und Gesundheit GmbH
    Inventors: Stefan Wintersperger, Robert Baier, Gerd Sutter, Marion Ohlmann, Volker Erfle
  • RECOMBINANT MVA VIRUS EXPRESSING DENGUE VIRUS ANTIGENS, AND THE USE THEREOF IN VACCINES
    Publication number: 20030082205
    Abstract: Recombinant MVA viruses containing and/or capable of expressing dengue virus antigens and the use of such recombinant MVA for vaccination.
    Type: Application
    Filed: March 23, 1999
    Publication date: May 1, 2003
    Inventors: MARY JANE CARDOSA, GERD SUTTER, VOLKER ERFLE
  • Recombinant MVA virus, and the use thereof
    Publication number: 20030035792
    Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.
    Type: Application
    Filed: May 15, 2002
    Publication date: February 20, 2003
    Applicant: GSF-Forschungszentrum Fur Umwelt und Gesundheit GmbH
    Inventors: Gerd Sutter, Marion Ohlmann, Volker Erfle
  • Recombinant MVA virus, and the use thereof
    Patent number: 6440422
    Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.
    Type: Grant
    Filed: January 2, 1998
    Date of Patent: August 27, 2002
    Assignee: GSF-Forschungszentrum fur Umwelt und Gesenudheit GmbH
    Inventors: Gerd Sutter, Marion Ohlmann, Volker Erfle